PinPoint

Name: PinPoint
Brand: PinPoint
Price: 8000.00 USD
Availability: InStock

MRRdeals Score · 49/100

Mobile Apps·Founded Jun 2026·Revenue rank #3,787

Share on X

View on TrustMRR

Share on X

MRR

$147/mo+118.9%

Asking

$8K

$MRRdeals score

49/100

What this SaaS is

Tracks peptide, TRT, and GLP-1 injections, estimated levels, vial supply, protocols, and reminders.

SubscriptionA mobile-app operator with experience in health and wellness subscriptions who can grow acquisition while maintaining clear safety boundaries.

Key features

Injection logging
Estimated medication levels between doses
Vial supply tracking
Protocol scheduling
Dose reminders and widgets

Things to scrutinise

Founded <12mo ago— Less than 12 months of operating history. Retention is unproven.

Numbers that matter

MRR

$147/mo

Revenue 30d

$509

Cash actually collected

All-time

$1.2K

Active subscriptions

Total customers

—

Not reported by TrustMRR

Growth 30d

+118.9%

Profit margin

80%

Multiple

1.3x

Asking / ARR

Payback

67.9 mo

At current margin

At a glance

Founded

5 mo ago

Listed

15d ago

Payments

Revenuecat

Audience

B2C

Mobile app

App Store4.8(10 ratings)Version 2.2.9

Apple and Google keep 15–30% of subscriptions: check whether the revenue and margin above are before or after the store commission, and plan the transfer of the app and its subscriptions through App Store Connect or Google Play.

Websitepinpointdose.com

Founders

@rahulnk

@rahulnk· 146 followers

Tech stack

frontend

swiftswiftui

backend

revenuecat

Score breakdown

How the composite score above splits across seven independent signals. Each axis is graded 0-100. Hover for details.

Value29/100

Payback at the stated margin, asking multiple vs the category median, and profit margin. The heaviest axis: what you pay for what it earns.

Growth70/100

Revenue trend over the last ~90 days from our daily snapshots (30-day figure when history is short), capped so one spike can't dominate, minus a penalty for erratic revenue.

Traction39/100

Paying customers, revenue scale and traffic (log scales), plus live-site health (reachable pricing page, core pages, maintained site).

Moat44/100

AI-disruption risk, organic search presence, recurring B2B revenue; penalties for thin AI wrappers and no-code lock-in.

Operability48/100

How turnkey the takeover is: diversity of marketing channels, Merchant-of-Record status, team.

Risk57/100

Higher = safer. Business age, breadth of the customer base (concentration risk), recurring vs one-off revenue, known payment provider.

Market65/100

Structured market read across TAM, saturation, 3-year trend, and hype cycle, blended with our category momentum signal.

Market read

TAM
mid
A focused consumer tracker serves a growing but limited population of peptide, TRT, and GLP-1 users.
Saturation
growing
Specialized dosing apps are emerging, while general medication trackers already compete for users.
3y trend
growing
GLP-1 adoption and interest in hormone therapies are expanding demand for dose tracking.
AI disruption
vulnerable
Logging, reminders, and level estimates are readily replicated, though trusted history and workflows add friction.
Hype cycle
mainstream
GLP-1 and peptide interest is mainstream, with dedicated tracking apps still a niche category.